IMCD stock surged 9.1% to close at 96.58 after the Rotterdam-based specialty chemicals distributor published first-half 2026 results that outperformed market forecasts on several fronts.
The company recorded Q2 EBITA of 95.2 million, ahead of the analyst consensus of 96.0 million by roughly 6%, and representing a 17% recovery versus the year-ago quarter. Organic revenue rose 7.5% in the quarter, more than double the 5.0% that analysts had expected.
For the six-month period, operating EBITA increased to 95 million, an 8% gain on a constant currency basis. Reported revenue for the half-year reached 2,638 million, up 11% when adjusted for foreign exchange. Free cash flow strengthened markedly, climbing 28% to 222 million.
CEO Marcus Jordan framed the results positively, saying the company delivered "gross profit and EBITA organic growth alongside increased free cash flow generation," and reiterated confidence in continued profit growth despite an uncertain macroeconomic backdrop. That tone was welcomed by investors given earlier worries about the pace of volume recovery following a softer first quarter.
Analyst activity ahead of the release had already signalled growing optimism. UBS upgraded the stock prior to the results, citing an expected top-line inflection in Q2 and forecasting a gradual volume recovery across 2026-27. Other major houses including Barclays, Goldman Sachs, Kepler Capital, and Jefferies remained committed to Buy ratings going into the print.
The market reaction occurred against a mixed backdrop in Amsterdam. The AEX index was under pressure from weakness in the semiconductor sector, with ASML and BESI both trading lower after South Korean chipmaker SK Hynix disappointed investors overnight. Despite that sector weakness, IMCD registered one of the stronger moves on the exchange. Rival Azelis Group also traded higher, suggesting some positive read-across within specialty chemicals distribution. U.S. equity markets were broadly flat, providing a neutral global context.
Taken together, the combination of a decisive earnings beat, a robust free cash flow result, reassuring management commentary, and continued analyst support produced IMCD s largest single-session gain in recent months. The shares moved toward the top end of the intraday band, which spanned 90.00 to 97.26, and narrowed the gap to the 52-week high of 105.05.
Market and sector implications
The results and subsequent share-price reaction reinforce investor focus on profit recovery metrics - EBITA growth, organic revenue expansion, and free cash flow conversion - for specialty chemical distributors. In this instance, IMCD s stronger-than-expected top- and bottom-line trends appear to have supported its relative outperformance even as chip-sector weakness weighed on the broader Amsterdam index.
What remains clear from the report
- Q2 outperformance on EBITA and organic revenue versus consensus drove the immediate market response.
- Half-year measures show improvement on an adjusted basis for revenue and operating EBITA, and a material rise in free cash flow.
- Management commentary and pre-release analyst upgrades helped sustain investor confidence in a gradual volume recovery scenario.